FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome.
Epigenetics
FOXP3
IPEX syndrome
Regulatory T cells
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
12
07
2022
accepted:
21
12
2022
pubmed:
5
1
2023
medline:
3
3
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
Pathogenic FOXP3 variants cause immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a progressive autoimmune disease resulting from disruption of the regulatory T cell (Treg) compartment. Assigning pathogenicity to novel variants in FOXP3 is challenging due to the heterogeneous phenotype and variable immunological abnormalities. The number of cells with demethylation at the Treg cell-specific demethylated region (TSDR) is an independent biomarker of IPEX. We aimed to investigate if diagnosing IPEX at presentation with isolated diabetes could allow for effective monitoring of disease progression and assess whether TSDR analysis can aid FOXP3 variant classification and predict disease course. We describe a large genetically diagnosed IPEX cohort (n = 65) and 13 individuals with other monogenic autoimmunity subtypes in whom we quantified the proportion of cells with FOXP3 TSDR demethylation, normalized to the number with CD4 demethylation (%TSDR/CD4) and compare them to 29 unaffected controls. IPEX patients presenting with isolated diabetes (50/65, 77%) often later developed enteropathy (20/50, 40%) with a median interval of 23.5 weeks. %TSDR/CD4 was a good discriminator of IPEX vs. unaffected controls (ROC-AUC 0.81, median 13.6% vs. 8.5%, p < 0.0001) with higher levels of demethylation associated with more severe disease. Patients with other monogenic autoimmunity had a similar %TSDR/CD4 to controls (median 8.7%, p = 1.0). Identifying increased %TSDR/CD4 in patients with novel FOXP3 mutations presenting with isolated diabetes facilitates diagnosis and could offer an opportunity to monitor patients and begin immune modulatory treatment before onset of severe enteropathy.
Identifiants
pubmed: 36600150
doi: 10.1007/s10875-022-01428-w
pii: 10.1007/s10875-022-01428-w
pmc: PMC9957900
doi:
Substances chimiques
Forkhead Transcription Factors
0
FOXP3 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
662-669Subventions
Organisme : Wellcome Trust
ID : 105636/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 219606/Z/19/Z
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Front Immunol. 2012 Jul 31;3:211
pubmed: 23060872
J Allergy Clin Immunol. 2023 Jan;151(1):233-246.e10
pubmed: 36152823
Hum Mol Genet. 2017 Oct 1;26(R2):R216-R224
pubmed: 28977446
PLoS One. 2020 Oct 23;15(10):e0240190
pubmed: 33095809
Epigenetics. 2011 Feb;6(2):236-46
pubmed: 20962591
Lancet. 2015 Sep 5;386(9997):957-63
pubmed: 26231457
J Clin Invest. 2006 Jun;116(6):1713-22
pubmed: 16741580
J Autoimmun. 2012 Feb;38(1):49-58
pubmed: 22264504
Pediatr Diabetes. 2019 Nov;20(7):1035-1040
pubmed: 31322807
Eur J Hum Genet. 2022 Feb;30(2):142-149
pubmed: 34744166
Eur J Immunol. 2007 Sep;37(9):2378-89
pubmed: 17694575
Case Reports Immunol. 2020 Sep 9;2020:9860863
pubmed: 32963853
Clin Gastroenterol Hepatol. 2006 May;4(5):653-9
pubmed: 16630773
Sci Transl Med. 2018 Aug 1;10(452):
pubmed: 30068569
Diabetes Care. 2009 Jan;32(1):111-6
pubmed: 18931102
J Allergy Clin Immunol. 2008 Dec;122(6):1105-1112.e1
pubmed: 18951619
Front Pediatr. 2021 Feb 05;9:643094
pubmed: 33614561
J Allergy Clin Immunol. 2018 Mar;141(3):1036-1049.e5
pubmed: 29241729
Nat Rev Immunol. 2009 Feb;9(2):83-9
pubmed: 19114986
Front Immunol. 2018 Nov 01;9:2411
pubmed: 30443250
Front Immunol. 2019 Apr 11;10:316
pubmed: 31031743
Diabetes. 2022 Mar 1;71(3):530-537
pubmed: 34789499
Lancet Diabetes Endocrinol. 2016 Oct;4(10):862-72
pubmed: 27474216